VEGF Over-Expression by Engineered BMSC Accelerates Functional Perfusion, Improving Tissue Density and In-Growth in Clinical-Size Osteogenic Grafts by Largo, Rene' D. et al.
fbioe-08-00755 July 1, 2020 Time: 18:36 # 1
ORIGINAL RESEARCH
published: 03 July 2020
doi: 10.3389/fbioe.2020.00755
Edited by:
Dimitrios I. Zeugolis,
National University of Ireland, Galway,
Ireland
Reviewed by:
Moyo Kruyt,
University Medical Center Utrecht,
Netherlands
Xinluan Wang,
Shenzhen Institutes of Advanced
Technology (CAS), China
*Correspondence:
Andrea Banfi
Andrea.Banfi@usb.ch
Nunzia Di Maggio
Nunzia.DiMaggio@usb.ch
†Present address:
Rene’ D. Largo,
Department of Plastic Surgery, The
University of Texas MD Anderson
Cancer Center, Houston, TX,
United States
Oliver Harschnitz,
The Center for Stem Cell Biology,
Sloan-Kettering Institute for Cancer
Research, New York, NY,
United States
Celeste Scotti,
Novartis Institutes for Biomedical
Research, Basel, Switzerland
Sinan Gueven,
I˙zmir Biomedicine and Genome
Center, Dokuz Eylul University, I˙zmir,
Turkey
‡These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Tissue Engineering and Regenerative
Medicine,
a section of the journal
Frontiers in Bioengineering and
Biotechnology
Received: 02 February 2020
Accepted: 12 June 2020
Published: 03 July 2020
VEGF Over-Expression by
Engineered BMSC Accelerates
Functional Perfusion, Improving
Tissue Density and In-Growth in
Clinical-Size Osteogenic Grafts
Rene’ D. Largo1,2†‡, Maximilian G. Burger1,2‡, Oliver Harschnitz1,2†, Conny F. Waschkies3,4,
Andrea Grosso1,2, Celeste Scotti5†, Alexandre Kaempfen2, Sinan Gueven5†,
Gernot Jundt6, Arnaud Scherberich5, Dirk J. Schaefer2, Andrea Banfi1,2* and
Nunzia Di Maggio1*
1 Cell and Gene Therapy, Department of Biomedicine, Basel University Hospital and University of Basel, Basel, Switzerland,
2 Plastic and Reconstructive Surgery, Department of Surgery, Basel University Hospital and University of Basel, Basel,
Switzerland, 3 Institute for Biomedical Engineering, ETH and University of Zurich, Zurich, Switzerland, 4 Department
of Surgical Research, University Hospital Zurich, Zurich, Switzerland, 5 Tissue Engineering, Department of Biomedicine,
University Hospital of Basel, University of Basel, Basel, Switzerland, 6 Institute of Pathology, University Hospital of Basel,
Basel, Switzerland
The first choice for reconstruction of clinical-size bone defects consists of autologous
bone flaps, which often lack the required mechanical strength and cause significant
donor-site morbidity. We have previously developed biological substitutes in a rabbit
model by combining bone tissue engineering and flap pre-fabrication. However,
spontaneous vascularization was insufficient to ensure progenitor survival in the
core of the constructs. Here, we hypothesized that increased angiogenic stimulation
within constructs by exogenous VEGF can significantly accelerate early vascularization
and tissue in-growth. Bone marrow stromal cells from NZW rabbits (rBMSC) were
transduced with a retroviral vector to express rabbit VEGF linked to a truncated
version of rabbit CD4 as a cell-surface marker. Autologous cells were seeded in
clinical-size 5.5 cm3 HA scaffolds wrapped in a panniculus carnosus flap to provide
an ample vascular supply, and implanted ectopically. Constructs seeded with VEGF-
expressing rBMSC showed significantly increased progenitor survivival, depth of tissue
ingrowth and amount of mineralized tissue. Contrast-enhanced MRI after 1 week
in vivo showed significantly improved tissue perfusion in the inner layer of the
grafts compared to controls. Interestingly, grafts containing VEGF-expressing rBMSC
displayed a hierarchically organized functional vascular tree, composed of dense
capillary networks in the inner layers connected to large-caliber feeding vessels entering
the constructs at the periphery. These data constitute proof of principle that providing
sustained VEGF signaling, independently of cells experiencing hypoxia, is effective to
drive rapid vascularization and increase early perfusion in clinical-size osteogenic grafts,
leading to improved tissue formation deeper in the constructs.
Keywords: VEGF, bone marrow stromal cells, osteogenic grafts, vascularization, gene therapy
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INTRODUCTION
Bone grafts are crucial to treat bone tissue loss due to
trauma, surgery or other clinical conditions where physiological
bone repair is insufficient. Autografts are currently the gold
standard for bone repair, but this approach is often associated
with several limitations, including chronic pain at the harvest
site, neurovascular injury, structural weakness and the limited
amount of autologous bone available (Younger and Chapman,
1989; Giladi et al., 2018). Moreover, upon implantation in vivo,
a major hurdle, especially for large defects, is osteonecrosis due
to lack of an endogenous vascular network which can improve
host integration (Rouwkema et al., 2008). Grafts consisting of
bone tissue and an internal vascular network supplied by large
caliber vessels, called bone flaps, have been applied for surgical
reconstruction of large segmental defects (Sparks et al., 2017).
However, bone flaps also suffer from complications, including
insufficient mechanical strength, significant donor site morbidity,
as well as complicated surgical procedures to generate grafts
of a predefined shape (Bodde et al., 2003). Therefore, available
surgical strategies are currently insufficient and there is an unmet
clinical need to promote vascularized bone regeneration. Bone
tissue-engineering holds promise for the generation of osteogenic
grafts, combining osteogenic progenitors with biocompatible
scaffolds. For this purpose, bone marrow stromal cells (BMSC)
are a rich source of potent osteoprogenitors, able to produce
bone tissue both ectopically and orthotopically when associated
with ceramic biomaterials (Iaquinta et al., 2019). However, in
general this strategy has yet to prove effective in humans for
defects of clinically relevant size (i.e., a few cubic centimeters).
One significant issue underlying these failures is the lack of rapid
vascularization, which results in progenitor death and failure of
bone formation inside the graft at depths greater than about 1 mm
(Scheufler et al., 2008; Guven et al., 2011).
Several approaches to accelerate vascularization of tissue-
engineered bone grafts are currently being investigated, such
as surgical techniques (flap or arterio-venous loop fabrication),
biomaterial-based methods (scaffold micro-fabrication designed
to facilitate vascular in-growth) or co-culture of osteogenic and
vasculogenic progenitors inside the grafts (Rao and Stegemann,
2013; Almubarak et al., 2016). We have previously developed
biological substitutes of clinically relevant size in a rabbit
model by combining bone tissue engineering and flap pre-
fabrication (Scheufler et al., 2008). Autologous cell-based, large
bone flaps in rabbits were prefabricated using porous ceramic
scaffolds loaded with BMSC and wrapped by a panniculus
carnosus flap, as an ample exogenous vessel source. This led
to the formation of healthy bone tissue in the periphery of
the graft, a fibrotic area in the middle and necrosis in the
core, because of insufficient blood supply, despite the presence
of a highly vascularized panniculus carnosus layer placed
around the scaffolds.
Vascular Endothelial Growth Factor (VEGF) is the master
regulator of blood vessel growth and the key molecular target of
strategies to promote vascular network expansion in regenerative
medicine (Gianni-Barrera et al., 2020). Here, we test the
hypothesis that increased angiogenic stimulation from within the
core of bone constructs by VEGF can significantly accelerate early
vascular in-growth, improve graft perfusion and therefore ensure
cell viability deeper in the construct.
MATERIALS AND METHODS
Bone Marrow Harvest and rBMSC
Culture
The study was approved by the Animal Ethics Committee of the
Swiss Federal Veterinary Office1. Bone marrow was harvested
from 7 young adult New Zealand White (NZW) rabbits (Charles
River Laboratories, Kisslegg, Germany) with an average body
weight of 2.3 ± 0.2 kg. Animals were sedated by subcutaneous
administration of 25 mg per kg of body weight ketamine
hydrochloride (Ketaminol 5% R©ad us. vet., Veterinaria AG,
Zurich, Switzerland) and 2.5 mg per kg of body weight xylazine
(Narcoxyl 2% R© ad us. vet., Veterinaria AG, Zurich, Switzerland)
before transfer to the operating room, where inhalation
anesthesia was initiated with isoflurane (Forene R©, Abbott AG,
Baar, Switzerland). Transcutaneous arterial oxygen saturation
and heart rate were monitored with a pulse oximeter (NPB
290, Nellcor Puritan Bennett, Pleasanton, CA, United States)
fixed to a front limb. Before surgery, single shot antibiotic
prophylaxis with 15 mg per kg of body weight sulfadoxin-
trimethoprim (Borgal R© 24% ad us. vet., Veterinaria AG, Zurich,
Switzerland) and 0.05 mg per kg of body weight buprenorphine
(Temgesic R©, Essex Chemie AG, Luzern, Switzerland) for pain
relief were administered subcutaneously. After the area over
the iliac crests was shaved and prepped with povidone iodine
solution (Betaseptic R©, Mundipharma Medical Company, Basel,
Switzerland), bone marrow was harvested by repeated puncture
of both iliac bones (2–3 per side) using 20 gauge needles
and 20 ml syringes filled with 1 ml of heparin sodium
solution (Heparin-Na R© 5′000 IU/ml, B. Braun Medical AG,
Emmenbrücke, Switzerland), yielding average aspirate volumes
of 18 ± 4 ml (range: 13–24 ml) per animal. Fresh aspirates
were diluted with a double volume of phosphate buffered saline
(PBS, Gibco, Invitrogen Corporation, Basel, Switzerland), and
centrifuged, resulting in the elimination of supernatant fat,
blood clots, and small tissue particles. Nucleated cells were then
stained with crystal violet 2.3% (Sigma-Aldrich, Fluka Chemie
AG, Buchs, Switzerland), counted and plated at a density of
1 × 105 cells/cm2 on tissue culture flasks. In vitro culture
was performed in α-minimum essential medium (Gibco, Grand
Island, NY, United States) supplemented with 10% fetal bovine
serum and FGF-2 (5 ng/ml; R&D Systems, Minneapolis, MN,
United States). Before reaching cell confluency, rBMSC were
detached with 0.05% trypsin/0.01% EDTA (Gibco), counted
and replated at a density of 2 × 103 cells/cm2 for cell
in vitro expansion.
Cell Cycle Analysis
The proportion of actively cycling cells was determined by
measuring their nuclear DNA content by flow cytometry after
1http://bvet.admin.ch
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staining with propidium iodide as described before (Helmrich
et al., 2012). The data were analyzed using the cell cycle analysis
tool from FlowJo Software (Becton, Dickinson and Company)
using the Watson model. BMSC from three different rabbits from
duplicate dishes were analyzed at each time point.
Vector Construction
Total RNA was purified from 20 to 30 mg samples of rabbit
kidney and spleen tissue with the RNeasy Mini Kit (Qiagen,
Basel, Switzerland). cDNA was synthesized with Omniscript
Reverse Transcription Kit (Qiagen, Basel, Switzerland) according
to the manufacturer’s instructions. Full rabbit VEGF sequence
was not available. Watkins et al. described the complete CDS
of rabbit VEGF, but they used primers based on human VEGF
sequence for the amplification (Watkins et al., 1999). One
of the two partial sequences of rbVEGF we found on NCBI
matched with the 3′ end of Watkins’ VEGF sequence. The
forward primer was constructed based on the human sequence;
however, being the leading sequence, it would not interfere
with the final amino acid sequence. Full-length rbVEGF-165
was cloned from kidney-RNA by PCR using the following
primers: forward: 5′- TTT GGA TCC ATG AAC TTT CTG
CTG TCT T -3′; reverse: 5′- TTT CTC GAG TCA CCG
CCT CGG CTT GT -3′. PCR conditions were as follows:
94◦C× 2 min+ (94◦C× 30 s+ 58◦C× 30 s+ 72◦C× 60 s)× 40
cycles + 72◦C × 5 min. A truncated version of rabbit CD4,
comprising only the extracellular and transmembrane domains,
was generated by inserting a stop codon after codon 424 (NCBI
accession number NP_001075782). PCR was performed on
spleen cDNA with the following primers: reverse: 5′- CAA TTG
TCA TCA CCG GCA CTT GAC ACA G -3′; forward: 5′- GTT
TAA ACA TGA ACC GGA GAA TCT ACT -3′. PCR conditions
were: 94◦C× 2 min+ (94◦ × 40 s+ 52◦ × 40 s+ 72◦ × 60 s)× 5
cycles + (94◦C for 40 s, 58◦C for 40 s, and 72◦C for 60 s) × 30
cycles+ 72◦C× 5 min.
BMSC Retroviral Transduction
The amphotropic retrovirus was produced by Phoenix helper-
free packaging lines by transient transfection as previously
described (Pear et al., 1993). Rabbit BMSCs were infected
at high efficiency with the retroviral constructs according to
a previously published protocol (Springer and Blau, 1997).
In order to achieve the highest efficiency, transduction was
carried out few days after plating, when the cells had their
highest mitotic activity. rBMSC were cultured in 60-mm
dishes and were incubated with retroviral vector supernatants
supplemented with 8 µg/mL polybrene (Sigma-Aldrich) for
5 min at 37◦C and centrifuged at 1100 g for 30 min at
room temperature in the dishes, followed by fresh medium
replacement. The infection rate of the rBMSC after each
transduction round (0 to 6 rounds) was determined by FACS
analysis with mouse anti rabbit CD4-FITC conjugated antibody
(MCA799F, AbD Serotec).
Cell Sorting
Expression of truncated CD4 by individual cells was assessed
by staining transduced rBMSC with a specific antibody to
rabbit CD4 directly conjugated to fluorescein isothiocyanate
(MCA799F, AbD Serotec). 3–5× 105 cells were resuspended into
200 µl of 0.5% BSA and incubated with 5 µl of antibody for
20 min on ice. Data were acquired with a FACS Calibur flow
cytometer (Becton, Dickinson and Company) and analyzed using
FlowJo software (Becton, Dickinson and Company). Cell sorting
was performed with a FACS Vantage SE cell sorter (Becton,
Dickinson and Company).
Rabbit-VEGF ELISA Measurements
The production of rabbit-VEGF in cell culture supernatants was
quantified using a Quantikine mouse VEGF immunoassay ELISA
kit (R&D Systems Inc., Minneapolis, MN, United States). One
ml of fresh medium was incubated on rBMSCs cultured in 60-
mm dishes in duplicate for 4 h, filtered, and frozen. Results
were normalized by the number of cells in each dish and the
time of incubation.
3D Perfusion Seeding
Porous ceramic scaffolds (porosity: 80 ± 3%, pore size
distribution: 22%, 100 µm; 32%, 100–200 µm; 40%, 200–500 µm;
6%, 500 µm) made of 100% hydroxyapatite, with a Ca/P ratio
of 1.66 ± 0.5 (Engipore R©, Fin-Ceramica, Faenza, Italy2), were
fabricated in the shape of large tapered cylinders (30 mm height,
20 mm upper base diameter, 10 mm lower base diameter,
5.5 cm3 volume). Autologous expanded rBMSC were seeded in
tapered cylinders for each animal, using a previously described
bioreactor system (Wendt et al., 2003), based on the principle
of direct perfusion of a single cell suspension through the
interconnected pores of 3D scaffolds. Briefly, scaffolds were pre-
wetted in complete medium and press-fitted into custom-made
polycarbonate chambers (one scaffold per chamber), positioned
at the bottom of two vertical Teflon-columns and connected
with each other at their base through a U-shaped tubing. rBMSC
(naïve, control CD4 and VEGF-expressing) suspended in 10 ml
of medium were introduced into the bioreactor and perfused
through the ceramic pores in alternating directions at a flow
rate of 1.2 ml/min for 18 h using a standard syringe pump
(Programmable PHD 2000 R©, Harvard Apparatus, Holliston, MA,
United States). A seeding density of 10× 106 cells/cm3 of ceramic
was consistently used, corresponding to a total number of
55× 106 rBMSC for tapered cylinders. All 3D perfusion cultures
were incubated in humidified atmosphere at 37◦C/5% CO2.
Surgical Procedure
Cell-seeded ceramic scaffolds were retrieved from the bioreactor,
rinsed in PBS, placed in sterile Falcon tubes pre-filled with
PBS, and transferred to the operating room. After the surgical
site on the dorsum of animals was shaved, disinfected and
draped, a midline skin incision was made to expose the
panniculus carnosus. Three anteriorly pedicled 6.5-cm wide
and 8-cm long panniculus carnosus flap centered over an
axial vascular pedicle were raised: two flaps were located
cranially and one flap caudally. The cell-scaffold constructs
(one with VEGF-transduced BMSC, one with CD4 BMSC and
2www.finceramica.it
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one with naïve BMSC) were randomly assigned to one of
the three flap sites, wrapped with a panniculus carnosus flap
and covered by a semipermeable membrane (Biobrane R©, UDL
Laboratories Inc., Rockford, IL, United States). The membrane
material is permeable to oxygen and nutrients, and allows
drainage of exudate through small pores, thereby preventing
the accumulation of wound fluid and seroma formation. After
8 weeks, rabbits were euthanized by intravenous injection
of pentobarbital (Nembutal R© , Sanofi, Basel, Switzerland)
and constructs retrieved with the surrounding semipermeable
membrane. The vascular pedicle was isolated at the flap base and
inspected for patency. After division of the vascular pedicle, the
constructs were exposed and assessed macroscopically for signs
of infection and external vascularization.
Dynamic Contrast Enhanced MRI
Perfusion MRI was performed on a 3T clinical scanner (Siemens
Magnetom Verio) with a 15-channel transmit/receive kneecoil
with a dynamic 3D GE sequence (TE 1.38 ms, TR 3.8 s,
flip angle 15◦, spatial resolution 0.9 × 0.9 × 0.9 mm3,
dynamic scans sampled every 6 s, total 60 dynamic scans).
MRI signal change upon contrast-enhancement was analyzed
semi-quantitatively using the initial uprising slope of the signal
time curve as a measure of tissue perfusion ("wash-in") and
the initial area under the curve at 20 dynamic scans after
contrast arrival (AUC20) as a measure for blood volume fraction
after normalization to baseline. Slope and bolus arrival were
computed (after manual selection of contrast arrival time on the
signal time curves) using in-house MATLAB scripts (MATLAB
R2018a, MathWorks R©).
Microtomography
After explantation, constructs were fixed in 4%
paraformaldehyde overnight and stored in PBS until
micro-computed tomography (µ-CT) analysis. Data were
acquired by using a phoenix nanotom m scanner (General
Electric, Fairfield, CT) with 0.5-mm aluminum filtered x-rays
(applied voltage 70 kV; current 260 µA). Transmission
images were acquired during a 360◦ scan rotation with an
incremental rotation step size of 0.25◦. Reconstruction was
made using a modified Feldkamp algorithm at an isotropic
voxel size of 2.5 µm. Threshold-based segmentation and 3D
measurement analyses (bone mineral density and volume)
were performed using ImageJ software (Schneider et al.,
2012) with the BoneJ (Doube et al., 2010) and 3D Shape
(Sheets et al., 2013) extensions. The threshold employed
for the segmentation was set at 325 mg/cm3, as previously
determined to clearly distinguish between ceramic and newly
formed mineralized tissue (Scheufler et al., 2008). Three-
dimensional rendering of the structures was performed
using VGStudio MAX 2.2 software (Volume Graphics,
Heidelberg, Germany).
Histology and Immunohistochemistry
After µ-CT analysis, constructs were decalcified by 7% EDTA
and embedded in paraffin. The sections (7 µm thickness) were
stained with Masson’s trichrome staining (RAL Diagnostics,
Martillac, France). For immunofluorescence staining, sections
were first deparaffinized in Ultra-clear and then rehydrated in
graded ethanol. For antigen retrieval, sections were incubated
with 0.05% trypsin and 0.1% CaCl2 in water for 13 min
at 37◦C and 10 min at room temperature, then rinsed
3 × 10 min in 100 mM glycine and 2 × 2 min in PBS.
Blocking was performed for 1 h at room temperature with 5%
goat serum and 2% BSA in PBS/0.3% Triton. Sections were
then incubated for 1 h at room temperature with anti-rabbit
CD4 primary antibody (MCA799GA, Clone Ken-4, Bio-Rad,
Hercules, CA, United States 1:100) and subsequently for 1 h
with a fluorescently labeled secondary antibody (AlexaFluor 647,
Invitrogen, Carlsbad, CA, United States 1:200). Fluorescence
images were acquired with a Nikon Ti2 Eclipse epifluorescence
microscope (Nikon, Tokyo, Japan). The number of CD4+ cells
was quantified automatically on 5 representative images from
each of 3 concentric 1.5 mm-deep layers (outer, middle and
inner) in each construct (n = 4 constructs/group) using FIJI
software (ImageJ3) and normalized by the number of total cells
(detected by DAPI staining) or by the tissue area (mm2). To
assess vascularization, immunohistochemical staining for CD31
with a rabbit specific antibody (SC1506, Santa Cruz, 1:100)
was performed. After incubation with a biotinylated secondary
antibody and subsequently with an ABC-alkaline phosphatase
complex, the specific staining was revealed by using Fast Red
(all reagents from Dako, Bollschweil, Germany). Matched IgG
control antibody was used as a negative control.
Statistics
Data are presented as mean ± SEM. The normal distribution
of all data sets was assessed by the Shapiro-Wilk test and
the significance of differences was evaluated with analysis of
variance (ANOVA) followed by the Bonferroni test (for multiple
comparison), or with the Student’s t-test (for single comparisons);
p < 0.05 was considered statistically significant.
RESULTS
Optimization of rBMSC Transduction
VEGF expression throughout the osteogenic graft was ensured by
genetically engineering the seeded progenitors with a retroviral
vector (Helmrich et al., 2012), which integrates in the genome and
therefore is not lost upon cell expansion. Since retroviral vectors
efficiently transduce only dividing cells, we first determined
the earliest time after isolation and plating when rabbit BMSC
(rBMSC) enter the cell cycle and proliferation is at its peak. Cell
cycle analysis was performed on samples from 3 independent
donors starting from day 3 after the initial plating to the
time of first confluence, which was reached consistently by
day 10. rBMSC proliferation increased 5 days after isolation
(41.7 ± 7.3% of cycling cells), reproducibly reached a peak
by day 7 (58.5 ± 10.3%) and it was maintained until day 9
3http://fiji.sc/Fiji
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(41.9 ± 7.9%), after which replication declined with increasing
confluence (Figure 1A). Based on these results, we determined
the optimal time to start transduction to be on day 6 after
isolation. Cells were transduced twice per day up to six times
with a retroviral vector expressing a truncated version of rabbit
CD4 (trCD4), which was non-functional through removal of
the intracellular domain and acted as a convenient cell-surface
reporter gene (Misteli et al., 2010). The transduction efficiency
was evaluated after each round by FACS quantification of the
CD4-positive cells. More than half of the cells were transduced
after two rounds (56.7% ± 1.2%) and the number of CD4-
positive cells reached 70% after six rounds (70.1 ± 5.2%).
Although a plateau was not reached, it was determined that
six rounds of transduction would provide a suitable balance
between maximizing transduction efficacy and minimizing cell
manipulation and this protocol was used to generate all cell
populations for further analysis described below.
Generation of FACS-Sortable
VEGF-Expressing rBMSC
A bicistronic retroviral vector (Figure 1B) was constructed
carrying the cDNA for rabbit VEGF165 (VEGF) and the truncated
version of rabbit CD4 (trCD4), joined through an internal
ribosomal entry site (IRES) that allows the translation of both
proteins from the same mRNA at a fixed ratio (Banfi et al.,
2012). A retroviral vector expressing only trCD4 in the second
cistron was used to generate control cells. Freshly isolated
rBMSC from 4 individual animals were transduced according
to the optimized protocol previously described (Helmrich et al.,
2012). Using freshly produced viral vector supernatants, the
average transduction efficiency was 63.4 ± 20.9% with the
VEGF vector and 50.6 ± 16.2% for the control vector (n = 4).
Upon reaching the first confluence, rBMSC were FACS purified
in order to remove non-transduced cells and to yield pure
CD4-positive populations (Figure 1C), which were replated
for in vitro cell expansion. Removal of non-transduced cells
was done to ensure a homogeneous distribution of the signal
throughout the constructs, because VEGF binds tightly to
extracellular matrix and therefore remains highly localized in the
microenvironment around each producing cell in vivo and does
not diffuse through tissue (Ozawa et al., 2004; Gianni-Barrera
et al., 2020). Production of VEGF protein by VEGF-expressing
rBMSC was confirmed by ELISA (609.5 ± 284.6 ng/106 cells/day
of rabbit VEGF), whereas naïve and CD4-rBMSC secreted
background amounts (23.5 ± 22.9 and 24.2 ± 25.9 ng/106
cells/day, respectively).
Generation of the Osteogenic Constructs
Clinical-size osteogenic constructs were generated as previously
described (Scheufler et al., 2008) with tapered hydroxyapatite
cylinders of 2-cm diameter at the base, 1-cm diameter at the
top and 3.5-cm height (Figure 2A). Expanded rBMSC were
seeded using a perfusion bioreactor system (Figure 2B), which
is based on the principle of direct perfusion of a single cell
suspension through the interconnected pores of 3D scaffolds
and which has been shown previously to ensure a homogenous
cell distribution within the pores of the scaffolds (Wendt
et al., 2003). Naïve, VEGF-expressing and CD4-rBMSC were
generated from each of the four independent rabbit donors
(n = 4). Each rabbit received one construct for each condition
generated with its own autologous cells. Scaffolds were first
wrapped in a panniculus carnosus flap, which provided the
vascularization source for new vessels to invade the construct
from the outside toward the core, and further covered by a
semipermeable membrane and then implanted under the skin
of the dorsum of each rabbit donor for 8 weeks (Figure 2C).
The membrane employed in this study was used to avoid
uncontrolled sources of vascularization besides the panniculus
carnosus, since it is permeable to oxygen and nutrients, but
does not allow the invasion by surrounding blood vessels and
cells. At the moment of harvesting, all constructs appeared
viable, surrounded by a healthy panniculus carnosus layer, which
was not removed in order to preserve the vascular connections
with the scaffolds.
VEGF-Expressing rBMSC Increase the
Amount of Mineralized Tissue
Throughout the Construct in vivo
Constructs were harvested 8 weeks after implantation. Before
undergoing decalcification for histological procedures, the
constructs were analyzed by micro-computerized tomography
(µ-CT). The analysis was performed mid-way on the long
axis at a virtual cross-section of 1.5 cm and 3 concentric
sections, each 1.5-mm deep, were designed in order to
distinguish an outer, middle and inner layer (Figure 3A).
Tissue density was calibrated according to Houndsfield
units (HU) and color-coded (HU scale, Figures 3B–D).
Constructs containing VEGF-expressing rBMSC were
characterized by higher HU values reaching deeper in
the construct (evidenced by the areas colored in red and
orange in Figure 3D) compared to the Naïve (Figure 3B)
and CD4 control (Figure 3C) conditions. These data were
confirmed by quantification of the total tissue density
(Figure 3E). As expected, a gradual decrease in tissue
density could be observed at increasing depths from the
construct surface. However, VEGF expression induced a
consistently greater tissue density in all layers. Interestingly,
VEGF enabled the inner layer to reach a tissue density
similar or greater than the one of the more superficial layer
in control conditions (VEGF inner = 497.4 ± 38.7 mg/cm3
vs. Naïve outer = 486.1 ± 28.6 mg/cm3 and CD4
outer = 477.0 ± 33.3 mg/cm3). The increased tissue density
in each layer of the constructs containing VEGF-expressing
cells was due to a significant increase by about 25% in the
amount of mineralized tissue compared to the control conditions
(Figure 3F). On the other hand, the density of the mineralized
tissue itself was not different among the three conditions
(Figure 3G), showing that VEGF did not affect the quality
of the mineralized matrix, but enabled a greater amount of it
to be deposited.
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FIGURE 1 | (A) Assessment by flow cytometry of the proportion of cells in active proliferation (S/G2 phases) at different time points after initial plating (n = 3). (B)
Map of the bicistronic retroviral vector carrying the coding sequences of rabbit VEGF165 (rVEGF165) and of a truncated version of rabbit CD4 (tr.rCD4) linked through
an Internal Ribosomal Entry Sequence (IRES). (C) Representative FACS plots for transduced rBMSC (light blue and orange plots) and FACS purified populations
(blue and red plots) stained for CD4 as a marker of transduction; Isotype controls = black plots.
FIGURE 2 | (A) Porous ceramic scaffolds were fabricated in the shape of large tapered cylinders (30 mm height, 20 mm lower base diameter, 10 mm upper base
diameter, 5.5 cm3 volume). (B) Schematic representation of the perfusion bioreactor system used in the study, providing bidirectional alternating flow through the
construct chamber during cell seeding and culture. (C) Constructs were covered with a panniculus carnosus vascularized flap, insulated with a semipermeable
membrane and implanted subcutaneously in vivo.
VEGF Expression Increases Dense
Tissue Ingrowth
Tissue ingrowth and bone formation were assessed histologically
by Masson’s trichrome staining. Constructs loaded with naïve,
control CD4 and VEGF-expressing rBMSC were analyzed at
three different positions along the main axis of the constructs
in three independent rabbits and tissue invasion was quantified
on transverse sections at five standardized points within each
transverse section (red arrows in Figure 4A). Frank bone tissue
could not be detected in any condition, but dense collagenous
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FIGURE 3 | (A) For µ-CT analysis, 3 concentric sections, each 1.5-mm deep, were designed in order to distinguish an outer, middle and inner layer (size
bar = 5 mm). (B–D) Representative images of constructs containing naïve rBMSC (B), CD4- (C) and VEGF-expressing rBMSC (D), color-coded according to tissue
density (Houndsfield units, HU) (size bar = 5 mm); (E–G) Quantification of total tissue density (E), percentage of mineralized tissue (F) and density of mineralized
tissue (G) in the three concentric layers defined in panel (A) (n = 4, *p < 0.05). The red dashed lines in (E) represent the density values of empty scaffolds implanted
without any cells.
matrix could be observed to fill the scaffold pores in all
conditions, similar to pre-bone matrix not yet fully mineralized
(Figure 4B). However, the depth of growth of this dense tissue
was significantly different among conditions (Figure 4C). In fact,
while both naïve and control CD4 cells similarly generated dense
tissue in about the first 2.5 mm from the construct surface, VEGF-
expressing rBMSC promoted a 35% increase in the depth of
tissue invasion (3.52 ± 0.17 mm vs. naïve = 2.6 ± 0.25 mm
and CD4 = 2.59 ± 0.20 mm; p < 0.05 and <0.01, respectively).
A separate analysis of the data confirmed the reproducibility of
this trend in the individual rabbits (Figure 4D).
VEGF Expression Improves the Survival
of Seeded rBMSC
The survival of seeded progenitors was tracked by
immunofluorescent staining of the truncated CD4 marker
expressed from the retroviral vectors used to transduce both
the control CD4 and VEGF populations, which had been used
also for the FACS purification. The quantification of progenitor
survival was performed separately in 3 concentric sections, each
1.5-mm deep, in order to distinguish an outer, middle and inner
layer, similarly to the analysis of the µ-CT data above. As shown
in Figure 5A, rBMSC could be detected within the scaffold
pores in both groups 8 weeks after implantation. Quantification
of CD4 + cells showed that VEGF expression significantly
improved the survival of seeded progenitors by greater than
2-fold in the outer and middle layer, both in relation to the total
amount of cells within the pores (Figure 5B) and as absolute
amount of cells per mm2 of pore tissue (Figure 5C). However, the
most striking difference was observed in the inner layer, where
progenitor survival dropped to virtually zero in the controls, but
was maintained at levels similar to the middle layer by VEGF
expression (Figure 5C; Outer: CD4 = 232.6 ± 21.2 cells/mm2
vs. VEGF = 476.1 ± 56.7 cells/mm2, p < 0.01; Middle: CD4 =
164.4 ± 73.7 cells/mm2 vs. VEGF = 437.1 ± 64.7 cells/mm2,
p < 0.05; Inner: CD4 = 19.1 ± 19.1 cells/mm2 vs. VEGF =
307.1± 23.9 cells/mm2, p < 0.05).
VEGF-Expressing rBMSC Improve
Vascularization to the Core and Promote
Artery Formation in the Periphery
In order to determine whether better progenitor survival and
tissue growth could be consequent to improved vascularization
of the VEGF-expressing constructs, blood vessels were
visualized histologically by CD31 staining (Figure 6). By
the end of the experiment 8 weeks after implantation, some
blood vessels were present in most of the pores of the
scaffolds in all three conditions (red signal in Figure 6A).
However, the VEGF-expressing scaffolds were invaded
by much more abundant and denser vascular networks
throughout the depth of the constructs. Moreover, VEGF
overexpression promoted the formation of dense micro-
vascular capillary networks in the deeper areas (Figure 6B),
whereas both control conditions contained only rare small-
caliber vessels within the deep pores. Interestingly, the outer
shell of VEGF constructs was vascularized by large-caliber
vessels, with homogenous diameters and filled with red
blood cells, corresponding to arteries and veins, whereas
the morphology and frequency of vessels in the naïve and
CD4 constructs was similar between the outer and inner
regions (Figure 6C).
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FIGURE 4 | (A) Representative macroscopic pictures of graft sections stained with Masson’s Trichome. Red arrows indicate tissue invasion (size bar = 2 mm).
(B) Representative pictures of scaffold pores containing collagenous dense matrix (Masson’s trichrome staining, size bar = 100 µm). (C) Quantification of the
average depth of tissue ingrowth for the 3 conditions (n = 3, *p < 0.05, **p < 0.01). (D) Quantification of the depth of tissue ingrowth for the three individual rabbits
(Rb1-3) included in the overall analysis in panel (C).
VEGF-Expressing rBMSC Improve the
Depth of Functional Early Blood
Perfusion
The histological data on tissue growth and blood vessel
formation suggest that the beneficial effect of VEGF expression
may take place by improving blood flow to critically under-
perfused progenitors in the middle layer of the constructs,
thereby enabling their survival and differentiation. To verify this
hypothesis, early blood flow inside the constructs was measured
non-invasively by dynamic contrast enhancement in the MRI at
the crucial time of 1 week after implantation. The analysis was
performed similarly to the µ-CT data. Tomographic images were
selected mid-way on the long axis at a virtual cross-section of
1.5 cm and three concentric sections, each 1.5-mm deep, were
designed in order to distinguish an outer, middle and inner
layer. MRI signal intensity upon contrast agent injection was
analyzed in each layer over time (60 dynamic scans, Figure 7A)
and used to calculate tissue perfusion (Figure 7B) and the
blood volume fraction (Figure 7C; Cuenod and Balvay, 2013).
The results show that both tissue perfusion and blood volume
fraction were significantly increased in the outer and middle
layers of VEGF-expressing constructs compared to naïve and
CD4 controls. Interestingly, VEGF expression improved blood
flow in the middle layer to similar levels as in the outer layer of the
controls. Tissue perfusion was improved also in the inner layer
by VEGF, but it only reached levels similar to the middle layer
of the controls.
DISCUSSION
In this study, we show that sustained VEGF over-expression
in clinical-size osteogenic grafts by genetically modified rabbit
BMSC was effective to significantly: (1) increase the depth
of tissue ingrowth; (2) improve the long-term survival of
seeded progenitors and the formation of mineralized tissue;
(3) support the establishment of a hierarchical vascular
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FIGURE 5 | (A) Representative immunofluorescence images from the outer, middle and inner layers of graft sections stained for rbCD4 (red) to detect the seeded
progenitors and counterstained with DAPI (blue) to label nuclei (size bar = 100 µm); (B,C) quantification of the number of CD4+ cells, expressed as percentage (%)
of the total cell number (B) and as absolute number per mm2 of tissue area (C) in each layer (n = 4, *p < 0.05, **p < 0.01).
network, and (4) improve early blood perfusion in clinical-
size scaffolds.
Even though the initial growth of new vessels can be
quite rapid, sustained VEGF signaling for about 4 weeks is
required for their subsequent stabilization and ability to persist
indefinitely. In fact, if delivery is too transient, newly induced
vessels regress promptly upon cessation of the VEGF stimulus
(Gianni-Barrera et al., 2020). Therefore, rapid passive release
of recombinant factors from scaffolds is inadequate to ensure
new vessel persistence and a large body of work has focused on
different strategies to ensure controlled and sustained delivery
of angiogenic molecules (Martino et al., 2015). VEGF over-
expression in BMSC was previously shown to ensure sustained
angiogenic signaling and to promote vascularization in non-
clinical size osteogenic grafts implanted subcutaneously in nude
rats (Helmrich et al., 2013). However, it is not clear whether
such growth could be sufficiently fast and extensive to reach
the tissue depths required in clinical-size constructs, where the
rapid establishment of a vascular network is needed to ensure
progenitor cell survival in the core of the scaffold. In fact,
survival of the implanted cells in small constructs is supported
by the availability of surrounding vasculature within a short
distance. On the contrary, in constructs of clinically relevant
size (i.e., a few cubic centimeters) the distance for diffusion of
oxygen and nutrients is exceeded and vessel in-growth depends
on physiological VEGF upregulation by ischemic conditions
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FIGURE 6 | Representative images of graft sections immuno-stained for CD31, showing blood vessels (in red), at low-magnification (A, size bar = 200 µm) and
high-magnification (B, inner layer and C, outer layer, size bar = 50 µm).
FIGURE 7 | Early blood flow inside the constructs assessed non-invasively by dynamic contrast-enhanced magnetic resonance imaging (DCE MRI) at 1 week after
implantation (n = 4). (A) DCE-MRI signal time-course for each layer in naïve, CD4 and VEGF-expressing constructs, expressed in arbitrary units (AU). (B) Tissue
perfusion computed from contrast “wash-in,” i.e., the initial uprising slope of the signal-time curve, expressed as the percentage increase over repetition time (%/TR).
(C) Blood volume fraction determined from the initial area under the normalized DCE curve at 20 dynamic scans after contrast arrival (AUC20) for each layer and
construct (*p < 0.05, **p < 0.01).
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generated inside the construct. However, this process is too
slow to ensure timely vascularization to significant depths,
causing cell death after transplantation and failure of tissue
formation (Sharma et al., 2019). We previously investigated
the potential of providing a highly vascularized tissue source
around the constructs (Scheufler et al., 2008). However, the
simple availability of abundant vascular networks around the
graft still requires endogenous upregulation of angiogenic signals
induced by ischemia to recruit new vessel growth inside the
construct. Therefore, bone formation was still limited to the outer
periphery and could not exceed about 1 mm of depth, while
only fibrous tissue was formed more deeply. Here, we tested the
strategy to combine a rich vascular supply around the implants
(panniculus carnosus) with angiogenic signals directly produced
by the osteogenic progenitors seeded throughout the scaffolds
in constructs of clinically relevant size (5.5 cm3). To this end,
rabbit bone marrow mesenchymal progenitors were genetically
modified with a retroviral vector to stably overexpress VEGF and
ensure consistent long-term expression despite cell expansion
(Helmrich et al., 2012). We have previously reported that
in vivo delivery of retrovirally transduced progenitors producing
therapeutic and functional levels of VEGF led to an increase in
tissue VEGF protein at least 6-fold higher than that induced by
ischemia alone (von Degenfeld et al., 2006). Indeed, our data
show that providing a VEGF signal throughout the construct,
independently of intervening hypoxia, promoted both the speed
and efficacy of vascularization of clinical-size constructs.
Crucially, the functional perfusion of inner layers was
significantly improved already by 1 week after implantation. In
fact, given sufficient time, all constructs are eventually invaded
by vessels to the inner layer (e.g., see Figure 5 after 8 weeks),
but perfusion within the first week determines whether seeded
progenitors survive (Rouwkema and Khademhosseini, 2016) and
recent data suggest that significant progenitor death may start as
soon as 3 days after implantation (Moya et al., 2018). The fact that
VEGF expression on one hand improved long-term progenitor
survival up to 8 weeks, and on the other increased functional
perfusion all the way to the inner layer several millimeters
inside the constructs within the first 7 days (Figure 7B) suggests
that vascular ingrowth can be a rather rapid process, given the
appropriate stimulation.
The functional significance of this increase in perfusion can be
understood by comparing its distribution within the constructs
with that of tissue formation. Under control conditions (Naïve
and CD4 cells) tissue formation took place to a depth of
about 2.5 mm (Figure 4C), indicating that blood perfusion
is required at a level between that of the outer and middle
layers (depths of 0–1.5 and 1.5–3.0 mm, respectively), whereas
the very little flow in the inner layer (3.0–4.5 mm depth)
is incompatible with progenitor survival, which in fact were
essentially absent in the inner layer of control grafts (Figure 5).
VEGF expression increased perfusion in all three layers, leading
the middle and inner layers to receive a similar blood flow as the
outer and middle layers of the control conditions, respectively
(Figure 7). Consistently with these changes, the survival of seeded
progenitors was significantly improved by VEGF expression
all the way through the inner layer and tissue formation was
promoted throughout the middle layer and into the inner layer,
to about 3.5 mm of depth. Although blood flow in the outer layer
of controls was already sufficient to enable tissue formation, the
increase due to VEGF expression appeared to be beneficial also in
this location, as evidenced by the improvement in tissue density
and mineralization (Figures 3E,F).
The accelerated kinetics of vessel growth afforded by VEGF
over-expression is also reflected in the different structure of the
definitive vascular networks visible after 8 weeks (Figure 6).
The slow growth in the naïve and CD4 conditions yielded
only a sparse microvascular network, with similar morphology
throughout the constructs. On the other hand, the robust and
rapid growth induced by sustained VEGF signaling led to
a hierarchically organized functional vascular tree, composed
of dense capillary networks in the inner layers, capable of
ensuring a robust exchange of nutrients and respiratory gases,
connected to large-caliber feeding vessels entering the constructs
at the periphery, which are necessary to supply effective blood
flow to the inner layers. In fact, the effective expansion
of the microvascular capillary bed by VEGF (angiogenesis)
has been shown to induce enlargement and recruitment of
feeding arteries (arteriogenesis) (Springer et al., 2003) both
through increased shear stress and gap junction-mediated
retrograde signaling along the vessel walls (Pries et al., 2010;
Annex, 2013).
One limitation emerging from this study is that osteogenic
differentiation did not reach the stage of frank bone. In all
groups the tissue that was formed displayed histological features
typical of osteogenic commitment of progenitors and clearly
distinct from fibrous tissue, namely the deposition of a dense
and homogeneous collagenous matrix, within which sparse cells
remained embedded (Figure 4B). Further, µ-CT analysis showed
density values typical of a mineralized matrix (500–600 mg/cm3
in the VEGF conditions; Figure 3E) and denser than both the
HA scaffold measured as a reference (<325 mg/cm3) and the
same scaffolds implanted without any cells (red dashed lines
in Figure 3E), thereby ruling out the possibility of pathological
calcification. This incomplete osteogenic differentiation was not
due to VEGF expression or the genetic modification of the
progenitors, as both VEGF and CD4 cells behaved similarly
to the naïve condition. Rather, the need to introduce a FACS-
purification step after retroviral transduction reduced the amount
of available rBMSC and required their expansion for >18
population doublings in order to obtain sufficient autologous
cells for each rabbit to seed 3 clinical-size constructs. Although
naïve cells did not require FACS purification, they underwent
the same degree of in vitro expansion in order to maintain
appropriate control conditions. In fact, it is well known that
BMSC dramatically lose their in vivo bone-forming capacity
during the first few passages of in vitro expansion (Banfi et al.,
2000). The importance of limiting BMSC in vitro culture can be
appreciated by comparing the results of previous experiments in
which the same constructs were seeded with the same amount of
naïve rBMSC expanded only until the first confluence (about 12
population doublings), where frank bone formation was observed
in 9/12 constructs (75%), albeit only to a depth of <1 mm
(Scheufler et al., 2008).
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In conclusion, these data constitute proof of principle that
providing sustained VEGF signaling, independently of cells
experiencing hypoxia, is effective to drive rapid vascularization
and increase early perfusion in clinical-size osteogenic grafts,
leading to improved progenitor survival and tissue formation
deeper in the constructs. However, when VEGF delivery is
achieved by genetic modification of the osteoprogenitors, the
necessary degree of in vitro expansion can reduce their in vivo
bone-forming capacity. Therefore, it would be desirable to
achieve sustained VEGF delivery in the constructs while limiting
in vitro manipulation of the osteoprogenitors. One strategy could
be to optimize further the genetic modification process to achieve
greater transduction efficiencies and avoid the FACS purification
step to eliminate non-transduced cells. In fact, retroviral vectors
infect only dividing cells, with greater efficacy the faster the cell
cycle (Springer and Blau, 1997), and rBMSC transduction was
limited to 70% despite targeting the protocol to the proliferation
kinetics. However, lentiviral vectors infect target cells regardless
of cell cycle status and allow more efficient transduction rates
(High and Roncarolo, 2019). Further, clinically compliant new
generation vectors, such as self-inactivating lentiviruses with
chromatin insulator elements providing a more attractive safety
profile, as they ensure stable and sustained transgene expression
without risks of insertional mutagenesis (De Ravin et al., 2016).
Another attractive strategy would be to avoid genetic
modification of progenitors altogether and to provide angiogenic
signaling by decorating the scaffold itself with recombinant
VEGF protein. For example, a variety of protein engineering
approaches have been developed to allow growth factor cross-
linking into fibrin matrices or to endow them with super-affinity
for extracellular matrix, effectively ensuring that morphogenic
signals are both protected from proteolytic degradation and
presented to their target cells in the physiological context of
matrix association (Martino et al., 2015).
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